Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 5, 2026Reported sale · Form 4Mary Miller, Chief Legal Officer · $585.1Open the filing ↗
- Aug 25, 2026Reported sale · Form 4Peter Blume-Jensen, President and CEO · $31.0KOpen the filing ↗
- Aug 25, 2026Notice of sale · Form 144Peter Blume-Jensen · Officer, Director · $30.6KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record31910 flagged findings
Reported transactions (Form 4)80since May 17, 2024 · and 10 other holdings
Corporate events (8-K)10since Nov 17, 2022
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
The 25 most recent filings (of 319)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Sep 2, 26Form 3 ↗Insider transaction
- Aug 27, 26Form 4 ↗Insider transaction
- Aug 25, 26Form 144 ↗Notice of proposed sale
- Aug 13, 26SCHEDULE 13G/A ↗Passive stake · Sands Capital Life Sciences Pulse Fund II, L.P. · 5.3% · event on Jun 30, 26 · amendment
- Aug 12, 268-K ↗Current report · Results
- Aug 12, 2610-Q ↗Quarterly report
Insider transaction · 9 Form 4 filingsshow all 9hide
- Aug 6, 26Form 4 ↗Insider transaction
- Jul 23, 26Form 4 ↗Insider transaction
- Jun 22, 26Form 4 ↗Insider transaction
- Jun 22, 26Form 4 ↗Insider transaction
- Jun 22, 26Form 4 ↗Insider transaction
- Jun 22, 26Form 4 ↗Insider transaction
- Jun 22, 26Form 4 ↗Insider transaction
- Jun 22, 26Form 4 ↗Insider transaction
- Jun 22, 26Form 4 ↗Insider transaction
- Jun 17, 268-K ↗Current report · A senior executive left or was appointed
- May 26, 26Form 4 ↗Insider transaction
- May 22, 26DEFA14A ↗Shareholder meeting and votes
319 filings on record, the oldest from Sep 12, 22.
Listing the 25 most recent filings of the 319 on record.
64
- Jun 17, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Mar 2, 26A material agreement was terminated8-K 1.02 ↗
- Mar 14, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Apr 9, 24Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Mar 4, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Feb 8, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Dec 8, 23Entered a material agreement8-K 1.01 ↗
- Jun 5, 23Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Nov 17, 22Sold unregistered shares+3 more in the same filing8-K 3.02 ↗
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- RA Capital Management, L.P.28.8%Apr 22, 26SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- Perceptive Advisors LLC9.9%Apr 29, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
- Kenneth Griffin5.5%Nov 14, 25SCHEDULE 13G ↗7 co-filers on this document — the figure is the largest single stake, not their sum.
- Sands Capital Life Sciences Pulse Fund II, L.P.5.3%Jun 30, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- Citadel Advisors LLC4.9%Sep 30, 25SCHEDULE 13G/A ↗7 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Aug 25, Peter Blume-Jensen filed notice of intent to sell up to $31K. That is about 0.03% of shares outstanding.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $31K on Aug 25, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
- Oct 5, 26Sell$585Mary MillerChief Legal Officer↗
- Aug 25, 26Sell$31KPeter Blume-JensenPresident and CEO↗
- Aug 18, 26Sell$2KPeter Blume-JensenPresident and CEO↗
- Aug 18, 26Sell$973Peter Blume-JensenPresident and CEO↗
- Aug 18, 26Sell$1KEric DevroeChief Operating Officer↗
- Aug 18, 26Sell$804Erick GamelinChief Development Officer↗
- Aug 18, 26Sell$372Mary MillerChief Legal Officer↗
- Aug 18, 26Sell$203Katharine PetersonChief Accounting Officer↗
- Aug 4, 26Sell$2KAdam D. LevyChief Financial Officer↗
- Jul 21, 26Sell$1KMary MillerChief Legal Officer↗
Stock compensation, tax and giftsshow the 30 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Aug 31, 26Compensationamount n/aMichaela LevinChief Business Officer↗
- May 21, 26Tax$25KPeter Blume-JensenPresident and CEO↗
- May 18, 26Compensationamount n/aPeter Blume-JensenPresident and CEO↗
- May 18, 26Compensationamount n/aPeter Blume-JensenPresident and CEO↗
- May 18, 26Compensationamount n/aEric DevroeChief Operating Officer↗
- May 18, 26Compensationamount n/aErick GamelinChief Development Officer↗
- May 18, 26Compensationamount n/aAdam D. LevyChief Financial Officer↗
- May 18, 26Compensationamount n/aMary MillerChief Legal Officer↗
- May 18, 26Compensationamount n/aMansoor Raza MirzaChief Medical Officer↗
- May 18, 26Compensationamount n/aKatharine PetersonChief Accounting Officer↗
- May 18, 26Compensationamount n/aCHARLES M BAUM↗
- May 18, 26Compensationamount n/aDerek DiRocco↗
- May 18, 26Compensationamount n/aIvana Magovcevic-Liebisch↗
- May 18, 26Compensationamount n/aSanthosh Palani↗
- May 18, 26Compensationamount n/aSharon Shacham↗
- May 18, 26Compensationamount n/aMICHAEL JOHN TOMSICEK↗
- May 18, 26Compensationamount n/aRA CAPITAL MANAGEMENT, L.P.↗
- May 14, 26Tax$2KPeter Blume-JensenPresident and CEO↗
- May 14, 26Tax$941Peter Blume-JensenPresident and CEO↗
- May 14, 26Tax$1KEric DevroeChief Operating Officer↗
- May 14, 26Tax$776Erick GamelinChief Development Officer↗
- May 14, 26Tax$353Mary MillerChief Legal Officer↗
- May 14, 26Tax$190Katharine PetersonChief Accounting Officer↗
- Apr 22, 26Compensation$7.0MRA CAPITAL MANAGEMENT, L.P.↗
- Apr 17, 26Tax$993Mary MillerChief Legal Officer↗
- Feb 21, 26Tax$22KPeter Blume-JensenPresident and CEO↗
- Feb 14, 26Tax$2KPeter Blume-JensenPresident and CEO↗
- Feb 14, 26Tax$944Peter Blume-JensenPresident and CEO↗
- Feb 14, 26Tax$1KEric DevroeChief Operating Officer↗
- Feb 14, 26Tax$768Erick GamelinChief Development Officer↗
The full record holds 140 transactions and goes back to May 31, 23.
Its sector and its market
Acrivon Therapeutics Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Acrivon Therapeutics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Acrivon Therapeutics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 319 documents on file, from Sep 12, 2022 to Oct 7, 2026.
- Company description
- No description available.
- This page
- Generated on Oct 18, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.